Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06921759 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
A Phase 3 study of Atopic Hand and Foot Dermatitis, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT06921759 is a Phase 3 study of Atopic Hand and Foot Dermatitis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 206 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06921759, a Phase 3 study of Atopic Hand and Foot Dermatitis, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lebrikizumab
Study Locations (20)
Other
- CONEXA Investigacion Clinica S.A. - Buenos Aires
- Investigaciones Medicas Imoba Srl - Buenos Aires
- CIPREC - Buenos Aires
- Instituto de Neumonologia Y Dermatologia - Buenos Aires
- Psoriahue - Buenos Aires
- Fundación Respirar - Buenos Aires
Florida
- Encore Medical Research - Hollywood
- Research Associates of South Florida - Miami - Southwest 8th Street - Miami
- Renstar Medical Research - Ocala
Texas
- Progressive Clinical Research - San Antonio
- Texas Dermatology and Laser Specialists - San Antonio
- Complete Dermatology - Sugar Land
California
- First OC Dermatology Research Inc - Fountain Valley
- Dermatology Research Associates - Los Angeles
Illinois
- DeNova Research - Chicago
Indiana
- Southern Indiana Clinical Trials - New Albany
Michigan
- Revival Research Institute, LLC - Troy
Missouri
- MediSearch Clinical Trials - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06921759
The ClinicalTrials.gov registry entry for NCT06921759 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Hand and Foot Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06921759 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06921759 about?
NCT06921759 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis". The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-u...
What is the current status of trial NCT06921759?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2025-04-21. Estimated completion is 2026-09.
What conditions does trial NCT06921759 study?
This clinical trial studies the following conditions: Atopic Hand and Foot Dermatitis.
What interventions are being tested in trial NCT06921759?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT06921759?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06921759 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.